SK Bioscience climbs two notches in ESG evaluation, receives BBB rating

SK Bioscience Co., a biopharmaceutical arm of South Korea's SK Group, announced it has received a BBB rating in its latest environmental, social, and governance (ESG) evaluation from Morgan Stanley Capital International (MSCI).

The 2022 evaluation saw the firm improve two steps from its previous B rating, which was given in 2021.

MSCI has been evaluating listed companies worldwide for ESG management capabilities and commitment to sustainability since 1999, using 35 key issues in 10 ESG categories as indicators.

The evaluation is considered a globally recognized indicator of a company's ESG management capabilities and commitment to sustainability.

SK Bioscience's upgraded rating reflects its proactive efforts in enhancing the independence of its board and developing human resources.

"ESG management is now a crucial aspect for all world-class companies, and we aim to be a global leader by prioritizing stakeholder satisfaction and creating a positive business environment to promote global public health," said SK Bioscience CEO Ahn Jae-yong.

Write to Jeong Min Nam at peux@hankyung.com